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Abstract 
Designing adequate drug carriers has long been a major challenge for those working in 
drug delivery. In fact, since drug delivery strategies have evolved for mucosal delivery, 
as the outstanding alternative to parenteral administration, many new drug delivery 
systems have been developed which evidence promising properties to address specific 
issues. Colloidal carriers, such as nanoparticles and liposomes, have been referred to 
as the most valuable approaches. However, they still present some limitations, which 
can become more inconvenient as a function of the specific characteristics of 
administration routes. In order to overcome these limitations, we developed a new drug 
delivery system that results from the combination of chitosan nanoparticles and 
liposomes, in an approach of combining their advantages, while avoiding their 
individual limitations. These lipid/chitosan nanoparticles complexes are, thus, expected 
to protect the encapsulated drug from harsh environmental conditions while, 
concomitantly, providing its controlled release. To prepare these assemblies, two 
different strategies have been applied, one focusing on the simple hydration of a 
previously formed dry lipid film with a suspension of chitosan nanoparticles; and the 
other relying on the lyophilisation of both basic structures, nanoparticles and 
liposomes, with a subsequent step of hydration with water. The developed systems are 
all able to provide a controlled release of the encapsulated model peptide, insulin, 
evidencing release profiles which are dependent on their lipidic composition. Moreover, 
satisfactory in vivo results were obtained, confirming the potential of these newly 
developed drug delivery systems as drug carriers through distinct mucosal routes. 
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Introduction 
The efficient delivery of therapeutic peptides and proteins through routes other than the 
parenteral, has been one of the major scientific challenges in drug delivery research. 
Mucosal administration of these molecules has a number of advantages and many 
design strategies have been explored to administer these biomacromolecules by routes 
such as the oral, pulmonary and ocular (Jorgensen et al., 2006). The most valuable 
approach to address this purpose consists on the application of colloidal carriers like 
nanoparticles and liposomes (de la Fuente et al., 2008). 
Polymeric nanoparticles have reduced dimensions which provide them with extremely 
increased surface-to-volume ratio and surface functionality (Silva et al., 2007). 
Furthermore, they have been reported to increase drug absorption by reducing the 
resistance of the epithelium to drug transport in a localised area or by carrying the drug 
itself across the epithelium (Csaba et al., 2006). In this context, mucoadhesive 
polymers, such as chitosan, have been proven adequate materials to design suitable 
nanoparticulate carriers, facilitating their interaction with mucosal surfaces (Takeuchi et 
al., 2001b). Chitosan is a polysaccharide with reported ability to improve the 
permeation of macromolecules across epithelial barriers and chitosan nanoparticles 
have demonstrated excellent capacity for protein entrapment and to increase their 
absorption through the nasal, intestinal and ocular mucosa (Alonso and Sánchez, 
2003; de Campos et al., 2001; Fernández-Urrusuno et al, 1999a; Paolicelli et al., 
2009). However, one of the major limitations of these nanoparticles is their limited 
stability in the biological fluids, such as the gastrointestinal media (Issa et al., 2005). 
Liposomes are versatile structures which enable the protection of the encapsulated 
material and tend to be relatively innocuous, because they are comprised of naturally-
occurring lipids that are metabolised at endogenous level (Jiang et al., 2007; Torchilin, 
2005). Their organised structure (an aqueous core enclosed within one or more 
phospholipid bilayers) permits the association of drugs to both the aqueous and lipid 
compartments and drug release can usually be controlled, depending on the bilayers 
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number and composition (Courrier et al., 2002; Kirby and Gregoriadis, 1999). 
Moreover, their aqueous core ensures the preservation of proteins structure and 
conformation, while the external lipids might help improving absorption across 
biological barriers (El-Maghrabya et al., 2008; Fenske et al., 2008; Gregoriadis, 1988). 
Nevertheless, one of the most reported problems of liposomes is their lack of stability in 
terms of leakage of the encapsulated drug (Gabizon, 1995). In fact, if liposomes’ inner 
core was solid instead of liquid, leakage would decrease dramatically, since drug 
release would imply an extra step of release from the solid core, followed by the 
traditional diffusion across the lipid bilayer (Campbell et al., 2004; Huang et al., 2005). 
In this manner, we have decided to combine the advantages of each of the described 
colloidal systems under the form of a single and new drug delivery system, which 
assembles the chitosan nanoparticles in lipid vesicles (liposome-chitosan nanoparticles 
complexes) (Carvalho et al., 2001). This system should permit an efficient 
encapsulation of therapeutic macromolecules, ensuring at the same time their stability 
and, ideally, providing a controlled release. As expected, as the phospholipidic bilayer 
comprises an extra barrier that should be overpass before release, phospholipids 
provided a controlled release of the encapsulated model protein, insulin (Grenha et al., 
2008a), and also permitted the stability in biological fluids. Moreover, the complexes 
demonstrated very low toxicity in ocular epithelial cells (Diebold et al., 2007).  
Depending on the administration objective (oral, ocular or lung delivery), different 
methodologies have been established to prepare the lipid/chitosan nanoparticles 
complexes, which are described in detail in this paper. 
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Methods 
Preparation of liposome-chitosan nanoparticle (L/CS-NP) complexes 
Preparation of chitosan nanoparticles (CS-NP) 
CS-NP are prepared according to the procedure developed by our group, based on the 
ionotropic gelation of CS with tripolyphosphate (TPP), in which the positively charged 
amino groups of CS interact with the negatively charged TPP (Calvo et al., 1997). To 
do so, CS (hydrochloride salt, Protasan Cl 110 or Cl 213, FMC Biopolymer, Norway) is 
dissolved in purified water in order to obtain solutions of 1 or 2 mg/mL and the final 
CS/TPP mass ratio is adjusted to 6:1, by using TPP (Sigma Chemicals, USA) aqueous 
solutions of 0.42 and 0.84 mg/mL, respectively, for each concentration of chitosan. The 
spontaneous formation of nanoparticles occurs upon incorporation of 1.2 mL of the 
TPP solution in 3 mL of the CS solution, under mild magnetic stirring (Plate A-13 Serie 
D, SBS, USA) at room temperature. Insulin-loaded CS-NP are obtained following 
dissolution of the protein (bovine insulin, Sigma Chemicals, USA) in NaOH 0.01 M (0.9 
mg insulin/0.6 mL NaOH or 3 mg insulin/0.6 mL NaOH) and it’s subsequent 
incorporation in the TPP solution (0.6 mL TPP solution + 0.6 mL insulin solution). When 
insulin-loaded nanoparticles are produced, TPP solution is prepared in double 
concentration as compared with that of the blank particles, to achieve the same final 
concentration as used in those, upon mixing with the insulin solution. The insulin 
concentration in the TPP solution is calculated in order to obtain CS-NP with a 
theoretical content of 30% or 50% (w/w) insulin respective to CS. 
CS-NP are afterwards concentrated by centrifugation at 16000g on a 10 µl glycerol 
(Sigma Chemicals, USA) layer for 30 min at 15 ºC (Beckman Avanti 30, Beckman, 
USA). The supernatants are discarded and nanoparticles (sediment) are resuspended 
in 100 µl of purified water. When the final goal is lung administration, the application of 
the described small scale (3 mL CS + 1.2 mL TPP) to produce CS-NP is restricted to 
nanoparticles characterisation, while the production of nanoparticles for the assembly 
of lipidic complexes is achieved by means of a large scale production. In this case, 
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preparation of CS-NP involves adding 12 mL of the TPP solution to 30 mL of the CS 
solution (10-fold scaling-up) and maintaining the stirring conditions. Centrifugation is 
performed at 10000×g on a 100 µl glycerol layer for 40 minutes at 15 ºC and the 
particles are re-suspended in 300 µl of purified water. In all other applications, low 
scale production is used. 
Recommendation: the stirring conditions (speed and type of vial, most importantly) 
used in the moment of nanoparticles’ assembly and the conditions of centrifugation 
(speed, duration and amount of glycerol layer) are the most important in obtaining 
suitable nanocarriers both in the moment of formation and in that of resuspension. 
Therefore, a correct optimisation of the process depending on the involved materials, 
vials, etc., is advised.  
Another important detail is the type of chitosan to be used in the production of the 
particles. As chitosan exists under many different chemical structures (base, type of 
salt, molecular weight) and the chitosan type of structure determines the nanoparticles 
preparation variables, it is thus very important to make a complete optimisation of the 
process of obtaining adequate nanoparticles, concerning CS and TPP concentrations, 
CS/TPP mass ratio, time and speed of centrifugation, volume of resuspension, etc.  
 
Preparation of liposomes  
Lipid vesicles (empty liposomes) are produced by the technique of hydration of a dry 
lipid film (Beaulac et al., 1999; Marier et al., 2002), using water as hydrating solution. In 
some cases, extrusion is applied upon obtaining multilamellar liposomes in order to 
have size homogenization and liposomes with approximately the same size of the 
chitosan nanoparticles. The extrusion process (Lipex Biomembrane Inc., Vancouver, 
Canada) is performed under a nitrogen pressure of 100 – 500 lb/in2 at 60 ºC, and 
liposomes are extruded five times through polycarbonate membranes of 0.8 µm pore 
size and, consecutively, other five times through pores of 0.4 µm, until the desired 
vesicle size of around 0.4 µm is obtained. Various lipid mixtures are selected, 
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according to the corresponding L/CS-NP complexes to be prepared, using different 
combinations of dipalmitoylphosphatidylcholine (DPPC), diesteroylphosphatidylcholine 
(DSPC), dipalmitoylphosphatidylserine (DPPS), dimiristoylphosphatidylglycerol 
(DMPG) (Lipoid GMBH,Germany) and cholesterol (Sigma Chemicals, USA). In this 
manner, as shown in Table 1, three different liposomal formulations are produced for 
oral and ocular administration, using the following lipid combinations and molar ratios: 
L1 – DSPC:DPPS:Chol (6/0.1/4 molar ratio); L2 – DPPC:Chol (6/4 molar ratio); L3 – 
DSPC:Chol (6/4 molar ratio); while two formulations are prepared as controls for 
pulmonary administration; L4 – DPPC:DMPG (10:1 molar ratio) and L5 – DPPC.  
Table 1 
 
The selection of these combinations of lipids, in the case of the oral delivery, was 
driven by the necessity of having gastrointestinal resistant vesicles, since DSPC and 
DPPC possess saturated, relatively long fatty acid chains and high phase transition 
temperatures, making them stable in acidic and intestinal media (Aramaki et al., 1993). 
Moreover, the inclusion of negatively charged lipids aims to favour the interaction with 
chitosan nanoparticles and cholesterol is included in the formulations to increase the 
stability and the rigidity of the system (Kirby and Gregoriadis, 1999; Takeuchi et al., 
2001a). Respect to the lipids applied in the formulations intended for lung delivery, 
DPPC and DMPG were chosen as they are endogenous to the lung and principal 
constituents of the pulmonary surfactant. Furthermore, the molar ratios correspond 
approximately to the phospholipids proportions in the referred surfactant (McAllister et 
al., 1996; Wright and Clements, 1987) and, in this manner, the overall in vivo lung 
environment is simulated. It is important to mention that, in some cases, liposomes 
were used as controls of the L/CS-NP complexes, while in other occasions liposomes 
were produced as a part of the technology applied to produce the lipid/chitosan 
nanoparticles complxes, as occurs in the complexes formulated by lyophilisation.  
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In order to produce the liposomes, the referred mixtures of lipids are dissolved in 20 mL 
of chloroform in a round bottom flask, to a final lipid concentration of 0.3 mM and 0.12 
mM for cholesterol, when applicable (formulations for oral and ocular delivery – L1, L2 
and L3). Afterwards, 50 g of glass beads are added in order to increase the surface 
available for the formation of the dry lipid film. Subsequently, the organic solvent is 
evaporated under a nitrogen stream in a rotary evaporator (Buchi® R-114, Buchi, 
Switzerland) for a period of 3 hours, at temperatures between 55 ºC and 60 ºC and a 
homogeneous film is formed. Nitrogen is used to ensure removing all the traces of 
organic solvent. The resulting thin film is then hydrated for 30 min, using 10 mL of 
water, previously heated to a temperature above that of phase transition and the 
obtained vesicles are filtered under vacuum to separate them from the glass beads. 
Formulations prepared for oral and ocular delivery are subsequently extruded 
according to the procedure described above. All the formulations of liposomes are 
stored at 4 ºC until use. 
The applied temperatures of evaporation are established to be above the phase 
transition temperature of the lipids or lipid mixtures, so that more flexible vesicles can 
be obtained (Rodríguez and Xamaní, 2003). These transition temperatures can be 
easily found in the literature and correspond, for example, to 41 ºC for DPPC and 58 ºC 
for DSPC (Delattre et al., 1993). 
Recommendation: phase transition temperature of lipid mixtures is different from that of 
the individual lipids. Therefore, when using lipid mixtures, there is the need to find the 
transition temperature of the specific mixture and, in the absence of that information, 
the highest transition temperature of the lipids applied in the mixture should be 
considered, all the work being performed above that temperature. 
 
Preparation of L/CS-NP complexes by hydration  
The preparation of L/CS-NP complexes by the method of hydration of a lipid film 
consists of adding a suspension of previously prepared CS-NP to a dry lipid film. As 
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can be observed in Table 1, each of the presented lipidic combinations is used to 
produce the liposomal vesicles and the corresponding L/CS-NP complexes. However, 
instead of hydrating the dry lipid film with water, as for the liposomes, the assembly of 
L/CS-NP complexes is achieved by using a suspension of chitosan nanoparticles 
(unloaded or insulin-loaded) as hydrating phase (volume of 10 mL). Complexes for oral 
or ocular administration are produced with lipid/nanoparticles mass ratio of 2/1, while 
those intended for lung administration count with a mass ratio of 3/1.  
Figure 1 displays a schematic demonstration of the methodology of the assembly of the 
L/CS-NP complexes. In the case of the complexes for lung delivery, DPPC or a mixture 
of DPPC and DMPG (10:1 molar ratio) are dissolved in 20 mL of chloroform and the 
same procedure and characteristics described before for the preparation of liposomes 
are applied until obtaining a dry lipid film. This film is then hydrated for 30 min with a 
suspension of the CS-NP (unloaded or insulin-loaded), forming the L/CS-NP 
complexes (3/1, w/w). Immediately afterwards, the complexes are filtered under 
vacuum to allow their separation from the glass beads.  
Figure 1 
 
In order to provide an efficient pulmonary administration and simultaneously, increase 
the long-term stability of the formulation, the complexes are submitted to a further step 
of spray-drying to encapsulate these structures in dry powders with adequate 
properties for systemic lung delivery. In brief, a suspension of complexes is mixed with 
mannitol (mannitol/complexes = 80/20 (w/w), final solids content 2.1%), which acts as 
inert carrier, and this mixture is spray-dried (Buchi Mini Spray Drier B-290, Buchi, 
Switzerland) at an inlet temperature of 160 ºC. For further details please consult the 
original paper (Grenha et al., 2008a). 
Complexes for oral and ocular delivery are prepared in a similar manner, except for the 
absence of the process of spray-drying and the application of different combinations of 
lipids, as observed in Table 1.  
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As referred for the production of liposomes, the temperatures used for evaporation are, 
in all cases, adjusted in order to ensure that the complexes are assembled at 
temperatures above the phase transition temperature of all phospholipids of the 
formulation, enabling the production of more flexible structures (Rodríguez and 
Xamaní, 2003). The selection of phospholipids to be included in the lipid film 
surrounding the inner core composed of nanoparticles, which can have very different 
properties, especially concerning surface charges, dictates the type of covering, which 
can result either complete or only partial. Therefore, as demonstrated in Figure 2, we 
propose the production of different structures, depending on the phospholipids 
composing the film.  
Recommendation: different mass ratios between lipids and nanoparticles should be 
tested and optimised for each case and for each lipid composition, since the interaction 
of the various combinations of lipids with the nanoparticles might be different and 
determine the production of complexes with different properties. 
Figure 2  
 
Preparation of L/CS-NP by lyophilisation  
The preparation of L/CS-NP complexes by the method of lyophilisation involves the 
separate preparation of the basic systems, chitosan nanoparticles and lipid vesicles 
(liposomes), with a subsequent mixing of both structures in a suspension. 
Upon mixing aliquots of chitosan nanoparticles and phospholipid vesicles suspensions, 
a procedure of freeze-drying is applied in the presence of 5% trehalose, which acts as 
a cryoprotectant. The trehalose solution is prepared in double concentration in order to 
obtain the final concentration of 5 % upon mixing with the suspension of the basic 
systems.  
Two different lipid/nanoparticles mass ratios are used to prepare the complexes by this 
method, 1/1 and 2/1. In this review only results of the ratio 2/1 are shown. The obtained 
mixtures are freeze-dried (Labconco freeze-dryer, United States) under the following 
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conditions: a primary drying step of 48 h at -30 ºC and a secondary drying step until the 
temperature gradually ascends to +20 ºC. After obtaining the lyophilised powder, the 
L/CS-NP complexes are prepared by hydration of the powder with purified water, under 
vigorous vortexing. As shown in Figure 3, the complexes obtained by this method, are 
the result of a “sandwich” structure which is formed by the drying of the liposomes 
intercalated with the nanoparticles, assembling in the form of complexes upon 
hydration, which obliges the lipids to rearrange into bilayers surrounding the inner core 
composed of nanoparticles. Albumin labelled with fluorescein isothyocyanate (FITC-
BSA) was, in some cases, associated to chitosan nanoparticles, acting as a marker 
molecule.  
Figure 3  
 
Recommendation: One important detail in the freeze-drying step is the type of 
cryoprotectant to be used in the production of the systems. In previous studies, our 
group tested different cryoprotectants, such as dextran, sucrose, glucose and 
trehalose, all applied to optimise the freeze-drying of chitosan nanoparticles 
(Fernández-Urrusuno et al., 1999b). Specifically concerning the preparation of L/CS-
NP complexes, glucose and trehalose were tested, and trehalose demonstrated to be 
the most adequate to preserve the integrity of freeze-dried L/CS-NP complexes. The 
selection of the cryoprotectant has demonstrated to play a major role in the final 
properties of the developed systems and, thus, this optimisation is highly 
recommended. 
 
Characterisation of L/CS-NP complexes 
Morphological examination 
The morphological examination of the complexes is conducted by optical (Olympus 
BH-2, Japan) and transmission electron microscopy (TEM) (CM12 Philips, The 
Netherlands). For TEM observation, samples are mounted on copper grids previously 
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covered with Formvar films. To obtain adequate samples for viewing, three different 
steps should be optimised: sample addition to the grid, staining process and final 
washing. All these steps should be performed with drops of approximately 10 µL. 
Initially, the 10 μL sample should be placed in contact with the grid surface for a pre-
determined period, which is usually of 10 seconds. Afterwards, the drop is dried using a 
little piece of filter paper. The second step consists on the sample staining with 10 µL of 
a solution of 2% (w/v) tungstophosphoric acid (Sigma Chemicals, Germany) that 
contacts with the sample deposited on the grid for other 10 seconds. Finally, after 
drying the staining material, a subsequent step of washing with 10 µL of water is 
advised to remove the excess of tungstophosphoric acid (10 seconds once again). 
Upon the final drying of water, the grid should be placed on a proper grid storage box 
and stored in a dessicator, for a minimum of 12 hours, until use. An optimisation of 
observations can be performed by changing the contact time of the samples with the 
grid and of the staining material with the samples, and also the time of washing (for 
instance, washing for 20 seconds instead of 10). Moreover, more than one washing 
step can be performed if desired.  
 
Size measurements 
The size of formulations (liposomal vesicles and complexes) developed for oral or 
ocular delivery is determined by photon correlation spectroscopy using a Zetasizer 
3000 HS (Malvern, UK). In this case, the samples should simply be diluted to the 
appropriate concentration (setup by the equipment) with water and placed in an 
adequate cell for the measurement. Those formulations developed for lung delivery, as 
they have not been extruded and, thus, present a larger size, are analysed for their 
size using a Coulter counter (Coulter® Multisizer II, Coulter Electronics, UK), equipped 
with a tube with an orifice aperture of 50 μm. Each particle produces a voltage 
alteration when passing through the orifice, according to its volume, which is 
transformed in a size value. To perform the measurements, 20 μL of the complexes or 
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liposomes suspension are dispersed in 100 mL of the electrolyte Isoton II (filtered, 
phosphate-buffered saline solution PBS). The instrument is previously calibrated using 
Isoton II and monodisperse latex microspheres of 13 μm, both supplied by Coulter. 
Nanoparticles’ size was, in all cases, determined by photon correlation spectroscopy, 
using the Zetasizer 3000 HS and following the procedure described above for sample 
preparation. 
 
Zeta potential measurements 
Zeta potential measurements are performed by laser Doppler anemometry, using the 
Zetasizer® 3000 HS (Malvern, UK). Samples are diluted with KCl 0.1 mM to an 
adequate concentration, which is set by the equipment, and placed in the 
electrophoretic cell, where a potential of ± 150 mV is established. KCl must be filtered 
(0.22 µm) before dilution, as does the water, which is used to clean the cell between 
each measurement. Samples are prepared to approximately 5 mL and are introduced 
in the cell using a syringe. 
 
Surface characterisation 
The complexes’ surface was analysed in order to determine whether the lipids were 
completely or only partially coating chitosan nanoparticles, using two different and 
complimentary techniques, X-ray photoelectron spectroscopy (XPS, VG Escalab 250 
iXL ESCA, VG Scientific, UK) and static time-of-flight secondary ion mass spectrometry 
(TOF-SIMS, TOF-SIMS IV, Ion-Tof GmbH, Germany). CS-NP, DPPC and DPPC-
DMPG control vesicles, and L/CS-NP complexes (DPPC/CS-NP and DPPC-
DMPG/CS-NP) are placed on polished monocristaline silicon wafers, which are used 
as sample holders. XPS measurements are carried out using non monochromatic Al-
Kα radiation (hν = 1486.62 eV) and photoelectrons are collected from a take off angle 
of 90º relative to the sample surface. Measurements are performed in a Constant 
Analyser Energy mode (CAE) with a 100 eV pass energy for survey spectra and 20eV 
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pass energy for high resolution spectra. Charge referencing is done by setting the 
lower binding energy C1s photopeak at 285.0 eV C1s hydrocarbon peak. The high 
resolution spectra fitting is based on “Chi-squared” algoritm used to determine the 
goodness of a peak fit. The chemical functional groups identity is obtained from the 
high-resolution peak analysis of carbon-1s (C1s), oxygen-1s (O1s) and nitroge-1s (N1s) 
envelopes. The experimental conditions (X-ray source, power and analysis area) are 
kept constant for each analysis.  
For TOF-SIMS analyses, a pulsed Gallium primary ion beam (69Ga+) generated with a 
liquid metal ion gun working at 15 kV, is used to bombard the samples with 45º 
incidence respect to the sample surface. The obtained secondary ions are extracted 
with a 10 KV voltage and their time of flight from the sample to the detector is 
measured in a reflectron mass spectrometer. Electron flood gun charge compensation 
is necessary during measurements. A raster size of 500 µm × 500 µm is used and at 
least three different spots are analyzed under the “static” condition with ion doses of 
about ≈1012 ions/cm2. The calibration of the mass spectra in the positive mode is based 
on hydrocarbon peaks such as CH2+, CH3+, C2H2+, and C3H5+. The experimental 
conditions (ion type, beam voltage and primary ion dose) are maintained constant for 
each experiment and for compared spectra. 
 
In vitro release studies 
To estimate the release rate of insulin from CS-NP and L/CS-NP complexes,  
suspensions of these systems are incubated under dynamic conditions at 37 ºC in PBS 
pH 7.4 (which simulates the lung lining fluid) or simulated gastric fluid (U.S. 
Pharmacopoeia). Briefly, 0.1 mL of each formulation are incubated with 0.9 mL of 
gastric medium or 0.5 mL with 4.5 mL of PBS pH 7.4.  At appropriate time intervals, 
individual samples are filtered with a low protein binding filter (0.22 µmMillex® GV, 
Millipore Ibérica, Spain) and the amount of insulin released is evaluated by the 
MicroBCA protein assay (Pierce, USA), measuring the absorbances by 
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spectrophotometry (Shimadzu UV-Visible Spectrophotometer UV-1603, Japan) at 562 
nm. A calibration curve is made at each time interval using unloaded-nanoparticles and 
L/CS-NP complexes.  
 
Physical stability in simulated lacrimal fluid 
The physical stability of each formulation of L/CS-NP complexes developed for ocular 
delivery (L1, L2 and L3) was assessed in simulated lacrimal fluid composed of 0.18% 
KCl, 0.63% NaCl, 0.006% CaCl2.2H2O and 0.01% MgCl2.6H2O in distilled water, pH = 
7.4 ± 0.1 (van Haeringer, 1981). An aliquot of each diluted suspension of complexes 
was incubated in the fluid at 37 ºC, for 2 h, after which the complexes size was 
measured by photon correlation spectroscopy using the Zetasizer® 3000 HS.  
 
Evaluation of complexes cytotoxicity using the IOBA-NHC cell line 
The cytotoxicity of L/CS-NP complexes (L1, L2 and L3) was determined upon 
incubation with IOBA-NHC cells, an immortalized epithelial cell line from normal human 
conjunctiva. To do so, the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-
carboxyalinide (XTT) test (XTT assay kit, Sigma Chemicals, USA) was applied, 
measuring the production of yellow formazan crystals upon cleavage of XTT by the 
mitochondrial dehydrogenases of viable cells. Briefly, cells were seeded on 96-well 
plates at a density of 4 × 104 cells/well and incubated until confluency (approximately 
20h) with the appropriate culture medium (DMEM-F12 supplemented with 10% fetal 
bovine serum, 5000 U/mL penicillin, 5 mg/mL streptomycin, 2 ng/mL human EGF, 1 
μg/mL bovine insulin, 0.1 μg/mL cholera toxin and 0.5 μg/mL hydrocortisone). 
Afterwards, the cells were washed with supplement-free culture medium for 1 hour and, 
subsequently, 30 μL of CS-NP or L/CS-NP (0.25, 0.5 and 1 mg/mL) suspensions were 
added over the cells. After 15, 30 or 60 min incubation, the cells were washed three 
times with phosphate buffered saline (PBS) pH 5.0, containing 0.27% glucose. The 
cells were then incubated with 20 L of XTT solution composed of 1 mg/mL XTT in 100 
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L of phenol red-free RPMI culture medium. A solution of 0.005% benzalkonium 
chloride in DMEM/F-12 culture medium was used as a positive control. The cytotoxicity 
of the different L/CS-NP complexes tested was expressed as viability, calculated using 
the following formula: 
 
Cell viability (%) = 100 – [(ODtest / ODc) x 100]     (1) 
 
where ODtest is the optical density of those wells exposed to CS-NP or L/CS-NP 
complexes suspensions; and ODc is the optical density of those wells treated with 
supplement-free DMEM/F-12 medium. 
 
Cell uptake studies 
To evaluate the ability of L/CS-NP complexes to cross the plasma membrane and enter 
the cells, IOBA-NHC cells and primary cultures (PCs) of human conjunctival epithelium 
were exposed to the three L/CS-NP formulations developed for ocular delivery. 
Confluent monolayers of IOBA-NHC cells and 3-week-old PCs were washed out for 1 h 
with supplement-free DMEM/F-12 culture medium and then incubated for 15, 30 or 60 
min with 0.25, 0.5 or 1 mg/mL of the L/CS-NP formulations. L/CS-NP complexes 
uptake by the cells was analyzed immediately after incubation and after a 24 h 
recovery period in supplemented culture medium. 
After incubation, cells were washed three times with PBS pH 5.0, containing 0.27% 
glucose and, subsequently, with cold PBS, pH 7.4. They were then fixed in cold 
methanol (-20º C) for 10 min and cold acetone for 3 sec, followed by incubation with 
PBS pH 7.4, containing 0.27% glucose and 0.2% Tween-20® for 30 min. Cells were 
then counterstained with tetramethyl-rhodamine isothiocyanate (TRITC)-conjugated 
phalloidin (1:200) to identify the actin component of the cytoskeleton. Preparations 
were mounted and examined with a confocal laser scanning microscope (Carl Zeiss 
LSM310, Jena, Germany) equipped with a krypton-argon laser. FITC and TRITC were 
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excited with a 488 and 543 nm emission laser beam, respectively. Controls included 
culture medium-treated IOBA-NHC cells and PCs. To confirm the intracellular LCS-NP 
complexes location, stacks of serial 10 µm optical sections were captured along the Z-
axis, first using the 488 nm laser for green FITC emissions and then the 543 nm laser 
for red TRITC emissions. Z-series images were then projected as profiles 
superimposed with green and red images. 
 
In vivo hypoglycaemic effect: oral administration 
The in vivo evaluation of the therapeutic response to insulin upon oral administration of 
the L/CS-NP complexes was carried out using normal male Wistar rats (200-210 g), 
fasted overnight before the administration, but with free access to water. The rats were 
previously acclimatised in the place where the experiments are performed and the 
baseline blood glucose was determined. Only rats with normal blood glucose are used 
in the experiment. Four experimental groups were established, each composed of 
seven animals, which correspond to four different formulations to be administered: 1) 
control water, 2) insulin control solution in PBS pH 7.4, 3) insulin-loaded CS-NP, and 4) 
insulin-loaded L/CS-NP complexes. All the formulations are administered in a single 
dose directly to the stomachs of conscious rats, by means of a glass syringe fitted to a 
gastric cannula. In all cases, the required dose of insulin (10 UI/kg) is administered to 
the rats in a total volume of 1 mL. Blood samples are collected from the tail vein at 
different times after dosing (1, 2, 4, 6, 10 and 24 hours) and glycaemic levels are 
determined in the samples by the glucose-oxidase method (Glucose GOD-PAD kit, 
Spinreact, Spain). The serum glucose level at time zero is taken as a 100% glucose 
level.  
 
In vivo tolerance assay: ocular administration 
Female albino New Zealand rabbits weighing 2.0-2.5 kg were used to study the acute 
ocular tolerance to CS-NP, L1/CS-NP and L3/CS-NP complexes. Only the 
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concentration evidencing the best in vitro results (0.5 mg/mL) was studied. Rabbits are 
randomly divided into three groups of five animals, each receiving 30 µL of one of the 
three formulations in the right eye every 30 min for 6 h. The contralateral eye is used 
as control and receives no treatment. The animals are then euthanized by air embolism 
after being deeply anesthetized with an intramuscular overdose of anesthetic and 
paralyzing mixture of xylazine (20 mg/kg) and ketamine (200 mg/kg). Eyeball and lid 
tissues are removed and fixed in Davison’s fixative solution composed of 1 part glacial 
acetic acid, 2 parts 37% formaldehyde, 3 parts 95% ethanol and 3 parts distilled water. 
Following fixation, they are embedded in paraffin for pathology. Eyeball and lid sections 
(6 µm) are evaluated in a masked fashion according to the following criteria: alteration 
in any of the ocular surface epithelia (cornea, limbus, conjunctiva), edema in lid tissues, 
presence of inflammatory cells (eosinophils, neutrophils, mast cells, and lymphocytes) 
and any other abnormality. 
 
Results 
CS-NP (unloaded and insulin-loaded) developed to assemble the L/CS-NP complexes 
presented sizes around 400 nm and strong positive zeta potentials (from + 34 to + 44 
mV); and insulin was associated with high efficiencies (68 - 96%). 
 
Pulmonary route  
Control vesicles and L/CS-NP complexes composed of DPPC or DPPC:DMPG present 
sizes around 2 µm. As expected, given the inherent charges of the phospholipids, the 
physicochemical properties of the complexes are influenced by the phospholipid 
composition. In this respect, systems comprised of DPPC present a neutral or close to 
neutral charge (-7 to 0 mV), while those with DMPG present a strong negative charge 
(-54 to -36 mV).  
As compared to chitosan nanoparticles, which display a burst release of insulin in 15 
minutes, the L/CS-NP complexes provide a controlled release of the peptide, which is 
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more effective for the complexes containing the mixture DPPC-DMPG. In a general 
manner, the controlled release of the complexes, as compared to the nanoparticles, is 
explained by the presence of the phospholipid external layer, which represents an extra 
barrier for the drug diffusing from the nanoparticles before releasing completely from 
the drug delivery system. The ability of the complexes comprised of the mixture of 
phospholipids, which present an overall negative charge, to provide a further control 
over drug release, is attributed to the fact that the interaction with the positively 
charged nanoparticles is favoured, providing a complete lipid coating of these. In fact, 
the occurrence of a complete coating could be confirmed by the surface analysis of the 
complexes by the techniques of XPS and TOF-SIMS, which have also demonstrated 
the partial coating of complexes formulated with only DPPC. While complexes 
containing DPPC and DMPG evidence on their surface only chemical signals attributed 
to the phospholipids, those comprised of only DPPC, display some signals assigned to 
the chitosan nanoparticles, demonstrating that, in this latter case, only a partial lipidic 
coating is achieved (Grenha et al., 2008b). In this manner, the major role of 
electrostatic interactions as driving forces to control the organisation of the 
lipid/nanoparticles assemblies is clearly evident.  
It is important to mention that mannitol microspheres developed to act as carriers of the 
insulin-loaded L/CS-NP complexes to the lung present adequate aerodynamic 
properties for an efficient delivery of the complexes to the alveolar zone, where 
systemic absorption of the model peptide is expected to occur. The referred 
microspheres, which contain 20% of complexes and 80% of mannitol, display 
aerodynamic diameters between 2.1 and 2.7 µm and apparent tap densities as low as 
0.4 – 0.5 g/cm3, depending on the formulation of complexes to be encapsulated. 
Moreover, the L/CS-NP complexes are easily recovered from the mannitol 
microspheres by incubation in physiological medium simulating the lung lining fluid 
(PBS pH 7.4), without significant alterations in both the morphology and 
physicochemical characteristics. In addition, the microencapsulation process does not 
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have any effect on the insulin release profile (Grenha et al., 2008a). A previous work 
from our group concerning the microencapsulation of non-complexed insulin-loaded 
chitosan nanoparticles as a strategy in lung protein administration has proven 
successful following intratracheal administration to rats (Al-Qadi et al., 2009) and the in 
vivo evaluation of the presently developed complexes is currently being setup. 
 
Oral route: L/CS-NP complexes prepared by hydration 
The L/CS-NP complexes present sizes within 1.5 and 3 µm. L1/CS-NP and L2/CS-NP 
formulations have a negative zeta potential of –17.7 and –3.1 mV, respectively, while 
L3/CS-NP complexes are positively charged (+15.9 mV). 
Figure 4 displays the insulin release profile from NP and L/CS-NP formulations in 
artificial gastric juice. As expected, CS-NP release their payload very rapidly, due to 
chitosan behaviour in acidic pH (dissolution), but all L/CS-NP complexes formulations 
exhibit the ability to control the release of the peptide in a similar manner, which is 
justified by the presence of the lipidic coating, as was confirmed in the complexes 
designed for lung administration.  
Figure 4 
 
These formulations of complexes were administered in vivo to rats and, as depicted in 
Figure 5, different lipidic compositions reflect different hypoglycaemic responses. In 
concordance with the observed release behaviour, the formulation containing a 
negatively charged phospholipid (DPPS) (L1/CS-NP), exhibits a more pronounced and 
rapid reduction in plasma glucose levels (P < 0.05), which decreased to about 50% of 
the baseline, remaining unaltered for at least 24 hours. This profile suggests that, as 
also indicated by the zeta potential data and as confirmed by the XPS and TOF-SIMS 
analysis performed in the complexes for lung delivery, a complete lipidic coating of the 
NP was achieved, which comprises an extra barrier that has to be overcome before 
complete release. The behaviour of these complexes is noticeably different than that of 
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the other two formulations (L2/CS-NP and L3/CS-NP), although those also registered 
punctual significant differences as compared to the profiles displayed by the insulin 
solution and CS-NP. As expected, the administration of an insulin solution does not 
lead to significant hypoglycaemic effect, given the rapid degradation in the gastric fluid 
prior to absorption. 
Figure 5 
 
Oral route: L/CS-NP complexes prepared by lyophilisation 
CS-NP applied to prepare L/CS-NP complexes by lyophilisation have the same 
characteristics of those used in the hydration method. Liposomes display sizes around 
300-360 nm, with neutral or negative charge, the latter reflecting the presence of 
DPPS. The size and zeta potential of the produced L/CS-NP complexes reflect the 
interaction of lipids with CS-NP. The most important data to refer on these 
characteristics is that L1/CS-NP complexes have a zeta potential of +31 mV, while the 
other two are close to neutral.  
Again (as reported for the first method), in contrast with the CS-NP behaviour, all L/CS-
NP complexes exhibit the ability to control insulin release along time (Figure 6); the 
profile varying according to the composition of vesicles used to form the complexes. 
The formulation with the negatively charged surface (L1/CS-NP) displays the more 
rapid release; while the other two formulations provide a more controlled release of the 
peptide.  
Figure 6  
 
Zeta potential data previously suggested that the incorporation of the negatively 
charged phospholipid in the complexes (L1/CS-NP) does not favour the lipidic coating 
of the nanoparticles (as happened in the hydration method), because the complexes 
zeta potential in this case is very similar to that presented by the nanoparticles. The 
release profile confirms this, because this formulation is in fact the more ineffective in 
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controlling drug release. This behaviour seems to indicate that the complexes 
formation by the method of lyophilisation is very different from that of hydration, 
probably due to a much lower time for interaction between the different parts (lipids and 
nanoparticles). 
The described in vitro behaviour was in perfect agreement with the in vivo results. 
Upon oral administration of the complexes formulations to rats, although a different 
pattern of change in serum glucose levels was observed in each case (Figure 7), 
L2/CS-NP and L3/CS-NP complexes were those providing the more effective and long-
lasting hypoglycaemic effect. Glucose levels decreased to about 70% of basal, 
remaining unaltered until 24 h.  
Figure 7  
 
These studies have shown that the complexes formed by both methodologies 
(hydration and lyophilisation) present different structures, which are affected by the 
system composition and by the applied methodology. 
 
Ocular route  
To evaluate the application of the L/CS-NP complexes as drug vehicles by the ocular 
route, the complexes were prepared by lyophilisation. The systems were loaded with 
FITC-BSA with the goal of assessing the penetration of the complexes in the ocular 
epithelium, their cytotoxicity and in vivo tolerance. FITC-BSA loaded CS-NP present 
sizes around 400 nm, while liposomes vary within 290 and 420 nm, as a function of 
their lipid composition; resulting in L/CS-NP complexes between 400 and 750 nm. The 
complexes zeta potential varied within +5.8 and +14.7 mV. All the complexes 
formulations have demonstrated to remain stable in simulated lacrimal fluid for at least 
2 h and are present inside the cells as early as 15 min after incubation and more 
clearly at 30 min. The systems exhibited negligible toxicity in vitro and a good tolerance 
in vivo. These results point out L/CS-NP complexes as potentially useful drug delivery 
  23   
carriers through the ocular mucosa. For further details please consult the original paper 
(Diebold et al., 2007). 
 
Conclusions and Prospects 
We have developed attractive and simple methodologies to efficiently 
associate/incorporate chitosan nanoparticles within lipid vesicles. By means of a 
lyophilisation procedure or by performing the hydration of a dry lipid film, we obtain new 
assemblies (liposome-chitosan nanoparticle complexes) that can display different 
properties, as a function of the lipid composition applied in their formation. As 
expected, these complexes permit the efficient encapsulation of therapeutic molecules 
like insulin; offer great stability in biological fluids and provide a controlled release of 
their payload. Furthermore, their in vivo behaviour can be considered very promising. 
The oral administration of these newly developed complexes loaded with insulin, 
demonstrates their ability to provide an important reduction in plasma glucose levels. 
Furthermore, these complexes exhibit negligible in vitro toxicity in conjunctival epithelial 
cells and a good tolerance in vivo, which corroborates their potential as drug carriers to 
the epithelial surfaces (i.e. ocular and lung (alveolar) surface). 
Our strategy can be applied to other naturally-occurring polymeric nanoparticles that, in 
this manner, should benefit from the existence of an extra lipidic barrier, which will 
probably take place as a bilayer, being an excellent means of controlling the release 
pattern. This structure is favoured by the interaction between nanoparticles and 
phospholipids, since it has been reported that the solid cores have a strong ordering 
effect on the phospholipid molecules. 
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Table 1. Lipid molar ratio used in the preparation of liposomes (L) and respective 
liposome/chitosan nanoparticles (L/CS-NP) complexes.  
Formulation Delivery route Molar ratio 
L       Complexes DSPC DPPS DPPC DMPG Cholesterol 
L1      L1/CS-NP Oral/ocular 6 0.1   4 
L2      L2/CS-NP Oral/ocular 6    4 
L3      L3/CS-NP Oral/ocular   6  4 
L4      L4/CS-NP Pulmonary   10 1  
L5      L5/CS-NP Pulmonary   10   
DPPC – dipalmitoylphosphatidylcholine; DSPC – diesteroylphosphatidylcholine; DPPS - dipalmitoylphos-
phatidylserine; DMPG - dimiristoylphosphatidylglycerol 
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Figure legends 
Figure 1. Schematic preparation of liposome/chitosan nanoparticles (L/CS-NP) 
complexes by hydratation. 
Figure 2. Hypothetical structures corresponding to complexes obtained by the method 
of hydration of a lipid film: a) complete coating with one lipid layer; b) complete coating 
with more than one lipid layer; c) partial coating of the nanoparticles; d) coating of 
several particles within the same complex; e) absence of coating, two separated 
systems coexisting (nanoparticles and liposomes). 
Figure 3. Schematic preparation of liposome/chitosan nanoparticles (L/CS-NP) 
complexes by lyophilisation. 
Figure 4. Insulin release profile from () chitosan nanoparticles, () L1/CS-NP, () 
L2/CS-NP and () L3/CS-NP complexes prepared by the hydration methodology, in 
artificial gastric juice.   
Figure 5. Hypoglycemic effect following oral administration of () water, () insulin 
solution, () CS-NP, () L1/CS-NP complexes, () L2/CS-NP complexes and () 
L3/CS-NP complexes to rats (insulin dosis = 10 UI/kg, data represent mean  SEM, n = 
7). 
Figure 6. Insulin release profiles from () CS-NP, () L1/CS-NP, () L2/CS-NP and 
() L3/CS-NP complexes prepared by the lyophilisation method, in artificial gastric 
juice.  
Figure 7. Hypoglycemic effect following oral administration of () water, () insulin 
solution, () CS-NP, () L1/CS-NP, () L2/CS-NP and () L3/CS-NP complexes to 
rats (insulin dosis = 10 UI/kg, data represent the mean  SEM, n = 7). 
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